In the United States,<unk>  is indicated for the treatment of adults and children one month of age and older with paroxysmal nocturnal hemoglobinuria and for the treatment of adults and children one month of age and older with atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy (TMA). In the European Union,<unk>  is indicated in the treatment of adults with paroxysmal nocturnal haemoglobinuria: * in people with haemolysis with clinical symptom(s) indicative of high disease activity * in people who are clinically stable after having been treated with eculizumab for at least the past six months.
Ravulizumab
Brolucizumab
Satralizumab
Mogamulizumab
Natalizumab
Inebilizumab
Risankizumab
Tildrakizumab